Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07940369 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1, PF-07940369 or Placebo | EXPERIMENTAL | Multiple oral dosing |
| Cohort 2, PF-07940369 or Placebo | EXPERIMENTAL | Multiple oral dosing |
| Cohort 3, PF-07940369 or Placebo | EXPERIMENTAL | Multiple oral dosing |
| PF-07940369 and Placebo (Cohort 1) | EXPERIMENTAL | Single dose administration of PF-07940369 and placebo; Within a cohort, participants will receive up to 4 oral doses of PF-07940369 and up to 2 doses of placebo. |
| PF-07940369 and Placebo (Cohort 2) | PLACEBO_COMPARATOR | Single dose administration of PF-07940369 and placebo; Within a cohort, participants will receive up to 4 oral doses of PF-07940369 and up to 2 doses of placebo. |
| Name | Type | Description |
|---|---|---|
| PF-07940369 | DRUG | Oral Tablets |
| Placebo | DRUG | Oral Tablets |
Inclusion Criteria: * Male participants and female participants who are not of childbearing potential who are overtly healthy as determine by medical evaluation including medical history, physical examination, laboratory tests, and standard 12 lead electrocardiogram (ECG). * Body mass index (BMI) o...
PF-07940369 is an investigational small molecule being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development, studied in healthy adults to evaluate how different amounts of the medicine are tolerated and act in the body.
PF-07940369 is being studied for use in healthy adults. The clinical trials aim to learn how different amounts of the study medicine are tolerated and how it acts in the body. It is not approved for any condition and remains in clinical development.
PF-07940369 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. The company is conducting Phase 1 clinical trials of this investigational small molecule in healthy adults.
PF-07940369 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Two Phase 1 trials have been completed, both studying the drug in healthy adults to assess tolerability and pharmacokinetics.
PF-07940369 has been studied in two completed Phase 1 clinical trials: NCT06532383 and NCT07514156. Both trials were conducted in Belgium, enrolled healthy adults aged 18 years and older, and were randomized, double-blind, and placebo-controlled.
PF-07940369 is not known to be the same as any other drug. It is a distinct investigational small molecule developed by Pfizer. No alternative names have been reported for this compound in the clinical trial information.